Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAP2K1 | Q02750 | 10/20 | 0.53 |
| ▸ | MAP2K2 | P36507 | 6/20 | 0.53 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477061 | 0.85 | GAA (0.56) | GAAMAP2K1MAP2K2PIM1CAMK2B | |
| SCHEMBL909599 | 0.81 | CES2 (0.61) | GAAGPR27KDM4EHDAC1ALDH1A1 | |
| SCHEMBL17993972 | 0.81 | ALDH1A1 (0.46) | GAAMAP2K1MAP2K2GPR27PIM1 | |
| Hydrochloric Acid SCHEMBL29775858 | 0.79 | CES2 (0.59) | GAAGPR27KDM4EHDAC1ALDH1A1 | |
| SCHEMBL12678697 | 0.79 | GAA (0.58) | GAAKDM4EHTTRXFP1ALDH1A1 | |
| SCHEMBL29306646 | 0.79 | GAA (0.58) | GAAKDM4EHTTRXFP1HDAC1 | |
| SCHEMBL1003542 | 0.79 | GAA (0.58) | GAAKDM4EHTTRXFP1HDAC1 | |
| SCHEMBL22226016 | 0.79 | MAP2K1 (0.42) | GAAMAP2K1MAP2K2HTT | |
| SCHEMBL1350827 | 0.79 | MAOB (0.45) | MAP2K1MAP2K2GPR27 | |
| SCHEMBL17958307 | 0.78 | MAP2K1 (0.74) | MAP2K1MAP2K2PIM1CAMK2BHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743453-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | Pretzel Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250325542-A1 | INHIBITORS OF ANTIMOCROBIAL RESISTANCE AND METHOS USING SAME | BAYLOR COLLEGE MEDICINE (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2025015178-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2023250467-A2 | INHIBITORS OF ANTIMICROBIAL RESISTANCE AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-3660016-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-2655374-B1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2767531-B1 | Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2718279-B1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-9085539-B2 | Cyclic N,N′-diarylthiourea—androgen receptor antagonist, anti breast cancer composition and use thereof | R-PHARM OVERSEAS INC. | 2015-07-21 | — | — | US | disclosed |
| US-9073874-B2 | Cyclic N,N′-diarylthioureas and N,N′-diarylureas-androgen receptor antagonists, anticancer agent, method for preparation and use thereof | R-PHARM OVERSEAS INC. | 2015-07-07 | — | — | US | disclosed |
| US-9073874-B2 | Cyclic N,N′-diarylthioureas and N,N′-diarylureas-androgen receptor antagonists, anticancer agent, method for preparation and use thereof | R-PHARM OVERSEAS INC. | 2015-07-07 | — | — | US | disclosed |
| US-20140329858-A1 | Cyclic Urea Derivatives As Androgen Receptor Antagonists | NOVARTIS AG (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329858-A1 | Cyclic Urea Derivatives As Androgen Receptor Antagonists | NOVARTIS AG (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329858-A1 | Cyclic Urea Derivatives As Androgen Receptor Antagonists | NOVARTIS AG (CH) | 2014-11-06 | — | — | US | disclosed |
| EP-2767531-A1 | Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same | Ivachtchenko, Alexandre Vasilievich (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20130252992-A1 | CYCLIC N,N'-DIARYLTHIOUREA - ANDROGEN RECEPTOR ANTAGONIST, ANTI BREAST CANCER COMPOSITION AND USE THEREOF | R-PHARM OVERSEAS INC. | 2013-09-26 | — | — | US | disclosed |
| WO-2013084138-A1 | CYCLIC UREA DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-06-13 | — | — | WO | disclosed |
| EP-2597086-A1 | CYCLIC N,N'-DIARYLTHIOUREAS AND N,N'-DIARYLUREAS AS ANDROGEN RECEPTOR ANTAGONISTS, ANTI-CANCER AGENT, METHOD FOR PRODUCING AND USING SAME | Ivachtchenko, Alexandre Vasilievich (RU) | 2013-05-29 | — | — | EP | disclosed |
| US-20130116269-A1 | CYCLIC N,N'-DIARYLTHIOUREAS AND N,N'-DIARYLUREAS - ANDROGEN RECEPTOR ANTAGONISTS, ANTICANCER AGENT, METHOD FOR PREPARATION AND USE THEREOF | R-PHARM OVERSEAS INC. | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329858-A1 | Cyclic Urea Derivatives As Androgen Receptor Antagonists | AR, UTS2R, FSHR | GAA 4554/4885MAP2K1 4105/4885MAP2K2 3735/4885 |
| US-20130116269-A1 | CYCLIC N,N'-DIARYLTHIOUREAS AND N,N'-DIARYLUREAS - ANDROGEN RECEPTOR ANTAGONISTS, ANTICANCER AGENT, METHOD FOR PREPARATION AND USE THEREOF | AR, NR5A1, GNRHR | GAA 4877/4885MAP2K1 4322/4885MAP2K2 4299/4885 |
| US-20250325542-A1 | INHIBITORS OF ANTIMOCROBIAL RESISTANCE AND METHOS USING SAME | BPGM, PNMT, DDT | GAA 294/4885MAP2K1 3977/4885MAP2K2 3723/4885 |
| US-20130252992-A1 | CYCLIC N,N'-DIARYLTHIOUREA - ANDROGEN RECEPTOR ANTAGONIST, ANTI BREAST CANCER COMPOSITION AND USE THEREOF | AR, NR5A1, CYP19A1 | GAA 4880/4885MAP2K1 3719/4885MAP2K2 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.